NCT04525313

The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients

The Prediction Model of Avastin Plus Chemotherapy as First Line Treatment in Unresectable Ras Mutant Colorectal Liver Metastase (CRLM) Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 116 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients

Detailed description

Ras mutant unresectable CRLM patients with primary tumor resection followed by avastin in combination with chemotherapy were included in this study. The tumor response was assessed by local MDT group. Based on tumor response, 58 CRLM patients were classified into two groups (CR+PR vs SD+PD). Primary samples of the two group patients will be sequenced by mass spectrum. After MS sequencing, a prediction model will be estimated. Another 58 CRLM patients will be inclued for validation of the prediction model.

Conditions

• Colorectal Cancer
• Liver Metastases

Timeline

• Start date: 2020-08-01
• Primary completion: 2022-12-01
• Completion: 2022-12-01
• First posted: 2020-08-25
• Last updated: 2020-08-25